BeyondSpring Past Earnings Performance

Past criteria checks 0/6

BeyondSpring has been growing earnings at an average annual rate of 15.4%, while the Biotechs industry saw earnings growing at 19% annually. Revenues have been growing at an average rate of 47.6% per year.

Key information

15.4%

Earnings growth rate

25.2%

EPS growth rate

Biotechs Industry Growth17.0%
Revenue growth rate47.6%
Return on equityn/a
Net Margin-829.9%
Last Earnings Update30 Jun 2024

Recent past performance updates

Recent updates

Here's Why We're Watching BeyondSpring's (NASDAQ:BYSI) Cash Burn Situation

Jun 21
Here's Why We're Watching BeyondSpring's (NASDAQ:BYSI) Cash Burn Situation

BeyondSpring, Beyond Salvage

Feb 03

Circling Back On BeyondSpring

Nov 16

Upcoming News For BeyondSpring's Plinabulin Tees Up Big Potential Returns

Sep 18

BeyondSpring: Poor Trial Conduct And Lack Of Transparency Create Substantial Downside Risk

Sep 07

BeyondSpring's Plinabulin: Upcoming PDUFA And Positioning In The CIN Space

Aug 01

BeyondSpring EPS misses by $0.04

Jun 16

BeyondSpring reports positive plinabulin combo data for prevention of chemotherapy-induced neutropenia

Jun 07

FDA grants accelerated review to BeyondSpring's plinabulin combo application; shares up 8%

Jun 01

BeyondSpring EPS misses by $0.17

Apr 30

How Much Of BeyondSpring Inc. (NASDAQ:BYSI) Do Insiders Own?

Dec 22
How Much Of BeyondSpring Inc. (NASDAQ:BYSI) Do Insiders Own?

BeyondSpring: Would Be A Great Buy Except For The Perennial Need For Cash And Ensuing Dilution

Dec 15

BeyondSpring slides 9% on public offering pricing at $10.0/share

Nov 19

BeyondSpring under pressure on shares offering

Nov 17

BeyondSpring's plinabulin combo meets primary endpoint in neutropenia trial

Nov 16

Revenue & Expenses Breakdown

How BeyondSpring makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

NasdaqCM:BYSI Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Jun 242-16910
31 Mar 242-181012
31 Dec 232-211015
30 Sep 232-241018
30 Jun 232-281121
31 Mar 231-301223
31 Dec 221-331326
30 Sep 221-351526
30 Jun 221-462328
31 Mar 221-562833
31 Dec 211-643137
30 Sep 211-723640
30 Jun 211-683340
31 Mar 211-622639
31 Dec 200-612342
30 Sep 200-571546
30 Jun 200-521145
31 Mar 200-471039
31 Dec 190-38931
30 Sep 190-38931
30 Jun 190-44838
31 Mar 190-49744
31 Dec 180-55652
30 Sep 180-56554
30 Jun 180-57755
31 Mar 180-58956
31 Dec 170-92989
30 Sep 170-80877
30 Jun 170-67565
31 Mar 170-58356
31 Dec 160-12210
30 Sep 160-1029
30 Jun 160-928
31 Mar 160-816
31 Dec 150-816

Quality Earnings: BYSI is currently unprofitable.

Growing Profit Margin: BYSI is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: BYSI is unprofitable, but has reduced losses over the past 5 years at a rate of 15.4% per year.

Accelerating Growth: Unable to compare BYSI's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: BYSI is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-2.3%).


Return on Equity

High ROE: BYSI's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.


Return on Assets


Return on Capital Employed


Discover strong past performing companies